Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells - Bolton-Gillespie, Elisabeth; Schemionek, Mirle; Klein, Hans-Ulrich; Flis, Sylwia; Hoser, Grazyna; Lange, Thoralf; Nieborowska-Skorska, Margaret; Maier, Jacqueline; Kerstiens, Linda; Koptyra, Mateusz; Müller, Martin C.; Modi, Hardik; et al. (Blood, 2013)
Keywords: Animals; Antineoplastic Agents - therapeutic use; Benzamides - therapeutic use; Cells, Cultured; DNA Damage - drug effects; Drug Resistance, Neoplasm - genetics; Genomic Instability - drug effects; Genomic Instability - physiology; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology; Mice; Mice, Transgenic; Myeloid Neoplasia; Neoplastic Stem Cells - drug effects; Neoplastic Stem Cells - metabolism; Neoplastic Stem Cells - pathology; Neoplastic Stem Cells - physiology; Oxidative Stress - drug effects; Oxidative Stress - genetics; Piperazines - therapeutic use; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Pyrimidines - therapeutic use; Reactive Oxygen Species - metabolism